{"id":14651,"date":"2012-03-02T07:30:00","date_gmt":"2012-03-02T06:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/mylan-verso-l%c2%92italiana-rottapharm\/"},"modified":"2012-03-02T07:30:00","modified_gmt":"2012-03-02T06:30:00","slug":"mylan-verso-l%c2%92italiana-rottapharm","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/mylan-verso-l%c2%92italiana-rottapharm\/","title":{"rendered":"Mylan to the Italian Rottapharm"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><font face=\"Calibri\"><span style=\"line-height: 115%; font-size: 12pt\">Mylan, a group from Pittsburgh (USA) wants to acquire Rottapharm, a Lombard company owned by the Rovati family which, according to some estimates, could be worth around 2 billion euros. The Italian company, which has been the object of the unsuccessful interest of the funds <\/span><em><span style=\"line-height: 115%; font-style: normal; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; color: black; font-size: 12pt; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-bidi-font-style: italic\">private equity<\/span><\/em><span style=\"line-height: 115%; font-size: 12pt\"> like Avista, Carlyle and Clessidra, could take a different direction: not financial partners, but a pharmaceutical giant, like the American one, with a turnover of 5.5 billion dollars and a market capitalization of around 10 billion.<\/p>\n<p><\/span><\/font><\/p>\n<p style=\"text-align: justify\"><span style=\"font-family: &quot;Verdana&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; font-weight: normal; mso-bidi-font-weight: bold\"><em>(Il Sole 24 Ore Pag.31 \u2013 29\/02\/2012)<\/em>&nbsp; <\/span><img","protected":false},"excerpt":{"rendered":"<p>Mylan,&nbsp;gruppo di Pittsburgh&nbsp;(Usa)&nbsp;vuole acquisire Rottapharm, azienda lombarda della famiglia Rovati che, secondo alcune stime, potrebbe valere circa 2 mld di euro.&nbsp;L&rsquo;azienda italiana, che &egrave; stata oggetto dell&rsquo;interesse, senza successo, dei fondi private equity come Avista, Carlyle e Clessidra, potrebbe prendere una direzione diversa: non soci finanziari, bens&igrave; un colosso farmaceutico, come quello americano, con un &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14651"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14651\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}